– A 2025 Cochrane review including nine randomized trials (829 participants) evaluated intraperitoneal chemotherapy (IPC) for both prophylaxis and treatment of peritoneal disease in gastric cancer.
– IPC (mostly hyperthermic intraperitoneal chemotherapy, HIPEC) showed an apparent survival benefit (prophylactic HR 0.66; therapeutic HR 0.52), but certainty is very low because of risk of bias, indirectness, and imprecision.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
